SCHEMBL19899996

SCHEMBL19899996

O=C(Cl)c1c(-c2ccccc2C(F)(F)F)noc1C1CC1

nearest known ligand 0.51

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ NR1H4 Q96RI1 18/20 0.51
▸ GPBAR1 Q8TDU6 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30437797 1.00 NR1H4 (0.51) NR1H4GPBAR1
SCHEMBL30437487 0.91 GPBAR1 (0.44) NR1H4GPBAR1
SCHEMBL21195682 0.89 NR1H4 (0.54) NR1H4
SCHEMBL20031247 0.85 NR1H4 (0.52) NR1H4GPBAR1
SCHEMBL19899913 0.82 NR1H4 (0.55) NR1H4
SCHEMBL25942196 0.82 GPBAR1 (0.65) NR1H4GPBAR1
SCHEMBL30437429 0.82 NR1H4 (0.51) NR1H4GPBAR1
SCHEMBL19202558 0.82 NR1H4 (0.51) NR1H4GPBAR1
SCHEMBL25942183 0.81 GPBAR1 (0.52) NR1H4GPBAR1
SCHEMBL20031560 0.78 NR1H4 (0.48) NR1H4GPBAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115608-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS ARDELYX, INC. (US) 2025-04-10 — — US disclosed
US-12209088-B2 Hormone receptor modulators for treating metabolic conditions and disorders ARDELYX, INC. (US) 2025-01-28 — — US disclosed
CN-116854681-A Hormone receptor modulators for the treatment of metabolic conditions and disorders 阿德利克斯股份有限公司 2023-10-10 — — CN disclosed
CN-110177783-B Hormone receptor modulators for the treatment of metabolic conditions and disorders 阿德利克斯股份有限公司 2023-06-06 — — CN disclosed
US-20230139597-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS ARDELYX, INC. (US) 2023-05-04 — — US disclosed
US-20230139597-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS ARDELYX, INC. (US) 2023-05-04 — — US disclosed
EP-3954684-A1 PROCESS FOR THE PREPARATION OF HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS Ardelyx, Inc. (US) 2022-02-16 — — EP disclosed
EP-3504205-B1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS ARDELYX INC (US) 2021-08-04 — — EP disclosed
US-20210017177-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS ARDELYX, INC. (US) 2021-01-21 — — US disclosed
US-20210017177-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS ARDELYX, INC. (US) 2021-01-21 — — US disclosed
US-10793568-B2 Hormone receptor modulators for treating metabolic conditions and disorders ARDELYX, INC. (US) 2020-10-06 — — US disclosed
US-10793568-B2 Hormone receptor modulators for treating metabolic conditions and disorders ARDELYX, INC. (US) 2020-10-06 — — US disclosed
CN-110177783-A Hormone receptor modulators for the treatment of metabolic conditions and disorders 阿德利克斯股份有限公司 2019-08-27 — — CN disclosed
US-20190233420-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS ARDELYX, INC. 2019-08-01 — — US disclosed
US-20190233420-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS ARDELYX, INC. 2019-08-01 — — US disclosed
EP-3504205-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS Ardelyx, Inc. (US) 2019-07-03 — — EP disclosed
WO-2018039386-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS ARDELYX, INC. (US) 2018-03-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230139597-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS NR1H4, FXR1, GLP1R NR1H4 1/4885GPBAR1 10/4885
US-12209088-B2 Hormone receptor modulators for treating metabolic conditions and disorders NR1H4, FXR1, GLP1R NR1H4 1/4885GPBAR1 10/4885
US-10793568-B2 Hormone receptor modulators for treating metabolic conditions and disorders NR1H4, FXR1, GLP1R NR1H4 1/4885GPBAR1 11/4885
US-20190233420-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS NR1H4, FXR1, GLP1R NR1H4 1/4885GPBAR1 11/4885
US-20210017177-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS NR1H4, FXR1, GLP1R NR1H4 1/4885GPBAR1 10/4885
US-20250115608-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS NR1H4, FXR1, GLP1R NR1H4 1/4885GPBAR1 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback